Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity

MLA

Justin J. Frere, et al. “Leveraging the Antiviral Type I Interferon System as a First Line of Defense against SARS-CoV-2 Pathogenicity.” Immunity, vol. 54, Mar. 2021, p. 557–570.e5. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ef8ba90b7ac8be974a3344c2c09d97d7&authtype=sso&custid=ns315887.

APA

Justin J. Frere, Daniel Blanco-Melo, David H. Sachs, Knarik Arkun, Maryline Panis, Jean K. Lim, Skyler Uhl, Kohei Oishi, Benjamin R. tenOever, Daisy A. Hoagland, Rasmus Møller, Shu Horiuchi, & Ilona Golynker. (2021). Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. Immunity, 54, 557–570.e5.

Chicago

Justin J. Frere, Daniel Blanco-Melo, David H. Sachs, Knarik Arkun, Maryline Panis, Jean K. Lim, Skyler Uhl, et al. 2021. “Leveraging the Antiviral Type I Interferon System as a First Line of Defense against SARS-CoV-2 Pathogenicity.” Immunity 54 (March): 557–570.e5. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ef8ba90b7ac8be974a3344c2c09d97d7&authtype=sso&custid=ns315887.